Nanobac Life Sciences Announces Manufacturing Agreement With Medicorp for Nanobacteria Test Kits

Prepares for Clinical Trials and Expanded Distribution

Oct 04, 2004, 01:00 ET from Nanobac Life Sciences, Inc.

    TAMPA, Fla., Oct. 4 /PRNewswire-FirstCall/ -- Nanobac Life Sciences, Inc.
 (OTCPK: NNBP) is pleased to announce the signing of a Manufacturing Agreement
 with Medicorp, Inc., for the production of two blood tests for the detection
 of Nanobacteria.  Nanobac is transferring production of both the Nano-Capture
 ELISA assay and the Nano-Sero IgG ELISA assay from its Nanobac Oy research
 laboratory in Kuopio, Finland to Medicorp in preparation for FDA clinical
 trials and expanded distribution.  Medicorp is Canada's largest, independent
 ISO 9001-certified manufacturer and distributor of immunodiagnostic and
 microbiology products.
     "We are pleased to be able to work with Medicorp to scale-up production of
 our test kits in preparation for FDA clinical trials and for our distribution
 of our test kits outside the U.S., commented John Stanton, Nanobac's President
 and Chief Executive Officer.  "This move prepares us for increased production
 of our test kits in an ISO-9001-certified manufacturing facility.  This is a
 key step for the Company as we move from a research oriented company to one
 that rapidly develops and commercializes products."
     Nanobac has already signed a distribution agreement with Oxoid Ltd. for
 territories in Europe, Brazil and Australia.  Oxoid is one of the world's
 leading manufacturers and distributors of microbiological culture media and
 other diagnostic products. With corporate headquarters in Basingstoke,
 Hampshire, Oxoid Ltd is supported by a network of wholly owned sales and
 distribution companies in Europe, North and South America and Australia.
     Nanobac recently announced that an abstract entitled "Increased serum
 levels of Nanobacteria antibodies are associated with high coronary
 calcification score" has been accepted for presentation in an oral session at
 the American Heart Association (AHA) Scientific Sessions 2004 conference in
 New Orleans, LA, Nov 7-10, 2004. The research was performed by Stephen
 Epstein, MD and Jianhui Zhu, PhD at the Washington Hospital Center,
 Washington, DC.
     About Nanobacteria
     Nanobacterium sanguineum (nanobacteria) is the smallest self-replicating
 organism ever detected -- at 50 to 500 billionths of a meter, 1/100th the size
 of the smallest previously known bacteria. Nanobacteria have been implicated
 in a variety of human diseases associated with pathological calcification.
     Nanobacteria were first discovered in 1988 by a Finnish researcher, and
 Nanobac OY co-Founder Olavi Kajander, M.D., Ph.D. Medical microbiologist Neva
 Ciftcioglu, Ph.D. joined his team in 1991 and their corroborated work with
 nanobacteria over the past 13 years has put them at the forefront of research
 into this medically important pathogen. Their research established that the
 blood-borne nanobacteria forms slow-growing calcified colonies in arteries and
     Nanobac has identified two biomarkers of nanobacterial infection. These
 tests are being developed as the NB2 test, which is composed of the
 nanobacteria antigen test, and the nanobacteria IgG antibody test.
     About Nanobac Lifesciences
     Nanobac Life Sciences, Inc. is dedicated to improving people's health
 through the detection and eradication of Nanobacterium sanguineum
 (nanobacteria). The Company's pioneering research is establishing the
 pathogenic role of nanobacteria in calcification, particularly in coronary
 artery heart disease and vascular disease. Nanobac has identified two
 biomarkers of nanobacterial infection, and expects to file for FDA approval of
 its NB2(TM) ELISA assays to detect nanobacterial antigen and IgG antibody. It
 is also leveraging its proprietary knowledge and intellectual property to
 develop the first FDA approved therapeutic to detect and treat nanobacterial
 infection. The Company currently markets, through its wholly owned subsidiary,
 Nanobac Sciences, a patented nanobiotic regimen that it developed.
     Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more
 information, please visit our website at:
     About Medicorp
     MEDICORP is Canada's largest, independent ISO 9001-certified manufacturer
 and distributor of immunodiagnostic and microbiology products.  MEDICORP
 manufactures and markets state-of-the-art immunoassay products, Monoclonal
 Antibodies for Neuroscience and a broad line of Polyclonal Antibodies to
 Peptide and Steroid hormones in Canada and through distributors in Europe and
 Asia. MEDICORP's Free PSA [fPSA] assay has revolutionized the differential
 diagnosis of prostate cancer.
     Investors are cautioned that certain statements contained in this document
 as well as some statements in periodic press releases and some oral statements
 of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements"
 within the meaning of the Private Securities Litigation Reform Act of 1995
 (the "Act). Forward-Looking statements include statements which are predictive
 in nature, which depend upon or refer to future events or conditions, which
 include words such as "believes," "anticipates," "intends," "plans,"
 "expects," and similar expressions. In addition, any statements concerning
 future financial performance (including future revenues, earnings or growth
 rates), ongoing business strategies or prospects, and possible future Nanobac
 Life Sciences, Inc. actions, which may be provided by management, are also
 forward-looking statements as defined by the Act. Forward-Looking statements
 involve known and unknown risks, uncertainties, and other factors which may
 cause the actual results, performance or achievements of the Company to
 materially differ from any future results, performance or achievements
 expressed or implied by such forward-looking statements and to vary
 significantly from reporting period to reporting period. Although management
 believes that the assumptions will, in fact, prove to be correct or that
 actual future results will not be different from the expectations expressed in
 this report. These statements are not guarantees of future performance and
 Nanobac Life Sciences, Inc. has no specific intention to update these
      For more information contact:
      John Stanton or Alex Edwards
      Nanobac Life Sciences, Inc.
      Cynthia Isaac, PhD
      The Ruth Group

SOURCE Nanobac Life Sciences, Inc.